167 related articles for article (PubMed ID: 19840270)
1. Involvement of cannabinoid-1 and cannabinoid-2 receptors in septic ileus.
Li YY; Li YN; Ni JB; Chen CJ; Lv S; Chai SY; Wu RH; Yüce B; Storr M
Neurogastroenterol Motil; 2010 Mar; 22(3):350-e88. PubMed ID: 19840270
[TBL] [Abstract][Full Text] [Related]
2. A novel CB receptor GPR55 and its ligands are involved in regulation of gut movement in rodents.
Lin XH; Yuece B; Li YY; Feng YJ; Feng JY; Yu LY; Li K; Li YN; Storr M
Neurogastroenterol Motil; 2011 Sep; 23(9):862-e342. PubMed ID: 21726355
[TBL] [Abstract][Full Text] [Related]
3. Effect of cannabidiol on sepsis-induced motility disturbances in mice: involvement of CB receptors and fatty acid amide hydrolase.
de Filippis D; Iuvone T; d'amico A; Esposito G; Steardo L; Herman AG; Pelckmans PA; de Winter BY; de Man JG
Neurogastroenterol Motil; 2008 Aug; 20(8):919-27. PubMed ID: 18373655
[TBL] [Abstract][Full Text] [Related]
4. Effects of cannabinoid receptor-2 activation on accelerated gastrointestinal transit in lipopolysaccharide-treated rats.
Mathison R; Ho W; Pittman QJ; Davison JS; Sharkey KA
Br J Pharmacol; 2004 Aug; 142(8):1247-54. PubMed ID: 15249429
[TBL] [Abstract][Full Text] [Related]
5. Differential effects of CB(1) neutral antagonists and inverse agonists on gastrointestinal motility in mice.
Storr MA; Bashashati M; Hirota C; Vemuri VK; Keenan CM; Duncan M; Lutz B; Mackie K; Makriyannis A; Macnaughton WK; Sharkey KA
Neurogastroenterol Motil; 2010 Jul; 22(7):787-96, e223. PubMed ID: 20180825
[TBL] [Abstract][Full Text] [Related]
6. Naphthalen-1-yl-(4-pentyloxynaphthalen-1-yl)methanone (SAB378), a peripherally restricted cannabinoid CB1/CB2 receptor agonist, inhibits gastrointestinal motility but has no effect on experimental colitis in mice.
Cluny NL; Keenan CM; Duncan M; Fox A; Lutz B; Sharkey KA
J Pharmacol Exp Ther; 2010 Sep; 334(3):973-80. PubMed ID: 20571060
[TBL] [Abstract][Full Text] [Related]
7. Cannabinoids regulate intestinal motor function and electrophysiological activity of myocytes in rodents.
Lin X; Wang H; Li Y; Chen C; Feng Y; Fichna J
Arch Med Res; 2015 Aug; 46(6):439-47. PubMed ID: 26254701
[TBL] [Abstract][Full Text] [Related]
8. Activation of cannabinoid CB1 receptors suppresses the ROS-induced hypersensitivity of rat vagal lung C-fiber afferents.
Yeh CM; Ruan T; Lin YJ; Hsu TH
Pulm Pharmacol Ther; 2016 Oct; 40():22-9. PubMed ID: 27328978
[TBL] [Abstract][Full Text] [Related]
9. Cannabinoid CB2 receptors in the enteric nervous system modulate gastrointestinal contractility in lipopolysaccharide-treated rats.
Duncan M; Mouihate A; Mackie K; Keenan CM; Buckley NE; Davison JS; Patel KD; Pittman QJ; Sharkey KA
Am J Physiol Gastrointest Liver Physiol; 2008 Jul; 295(1):G78-G87. PubMed ID: 18483180
[TBL] [Abstract][Full Text] [Related]
10. The cannabinoid antagonist SR144528 enhances the acute effect of WIN 55,212-2 on gastrointestinal motility in the rat.
Abalo R; Cabezos PA; Vera G; Fernández-Pujol R; Martín MI
Neurogastroenterol Motil; 2010 Jun; 22(6):694-e206. PubMed ID: 20132133
[TBL] [Abstract][Full Text] [Related]
11. Cannabinoid receptor agonists modulate oligodendrocyte differentiation by activating PI3K/Akt and the mammalian target of rapamycin (mTOR) pathways.
Gomez O; Sanchez-Rodriguez A; Le M; Sanchez-Caro C; Molina-Holgado F; Molina-Holgado E
Br J Pharmacol; 2011 Aug; 163(7):1520-32. PubMed ID: 21480865
[TBL] [Abstract][Full Text] [Related]
12. Effects of Cannabinoid Agonists and Antagonists on Sleep and Breathing in Sprague-Dawley Rats.
Calik MW; Carley DW
Sleep; 2017 Sep; 40(9):. PubMed ID: 28934522
[TBL] [Abstract][Full Text] [Related]
13. In vitro and non-invasive in vivo effects of the cannabinoid-1 receptor agonist AM841 on gastrointestinal motor function in the rat.
Abalo R; Chen C; Vera G; Fichna J; Thakur GA; López-Pérez AE; Makriyannis A; Martín-Fontelles MI; Storr M
Neurogastroenterol Motil; 2015 Dec; 27(12):1721-35. PubMed ID: 26387676
[TBL] [Abstract][Full Text] [Related]
14. Central administrations of hemopressin and related peptides inhibit gastrointestinal motility in mice.
Li XH; Lin ML; Wang ZL; Wang P; Tang HH; Lin YY; Li N; Fang Q; Wang R
Neurogastroenterol Motil; 2016 Jun; 28(6):891-9. PubMed ID: 26991932
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of selective cannabinoid CB(1) and CB(2) receptor agonists in a mouse model of lipopolysaccharide-induced interstitial cystitis.
Tambaro S; Casu MA; Mastinu A; Lazzari P
Eur J Pharmacol; 2014 Apr; 729():67-74. PubMed ID: 24561047
[TBL] [Abstract][Full Text] [Related]
16. Virodhamine and CP55,940 modulate cAMP production and IL-8 release in human bronchial epithelial cells.
Gkoumassi E; Dekkers BG; Dröge MJ; Elzinga CR; Schmidt M; Meurs H; Zaagsma J; Nelemans SA
Br J Pharmacol; 2007 Aug; 151(7):1041-8. PubMed ID: 17558435
[TBL] [Abstract][Full Text] [Related]
17. AM841, a covalent cannabinoid ligand, powerfully slows gastrointestinal motility in normal and stressed mice in a peripherally restricted manner.
Keenan CM; Storr MA; Thakur GA; Wood JT; Wager-Miller J; Straiker A; Eno MR; Nikas SP; Bashashati M; Hu H; Mackie K; Makriyannis A; Sharkey KA
Br J Pharmacol; 2015 May; 172(9):2406-18. PubMed ID: 25572435
[TBL] [Abstract][Full Text] [Related]
18. Activation of cannabinoid receptor 2 reduces inflammation in acute experimental pancreatitis via intra-acinar activation of p38 and MK2-dependent mechanisms.
Michler T; Storr M; Kramer J; Ochs S; Malo A; Reu S; Göke B; Schäfer C
Am J Physiol Gastrointest Liver Physiol; 2013 Jan; 304(2):G181-92. PubMed ID: 23139224
[TBL] [Abstract][Full Text] [Related]
19. A synthetic cannabinoid, CP55940, inhibits lipopolysaccharide-induced cytokine mRNA expression in a cannabinoid receptor-independent mechanism in rat cerebellar granule cells.
Chiba T; Ueno S; Obara Y; Nakahata N
J Pharm Pharmacol; 2011 May; 63(5):636-47. PubMed ID: 21492165
[TBL] [Abstract][Full Text] [Related]
20. A novel peripherally restricted cannabinoid receptor antagonist, AM6545, reduces food intake and body weight, but does not cause malaise, in rodents.
Cluny NL; Vemuri VK; Chambers AP; Limebeer CL; Bedard H; Wood JT; Lutz B; Zimmer A; Parker LA; Makriyannis A; Sharkey KA
Br J Pharmacol; 2010 Oct; 161(3):629-42. PubMed ID: 20880401
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
